Dr. Ali Attiq, Universiti Sains Malaysia, Malaysia
Dr. Ali Attiq, PhD, is a seasoned molecular pharmacologist and pharmacist specializing in immunopharmacology, inflammation, and drug discovery. Currently a Senior Lecturer at Universiti Sains Malaysia, he investigates epigenetic programming of immune cells in the tumor microenvironment. 🎓 He earned his PhD in Pharmacy from Universiti Kebangsaan Malaysia and has held leadership roles at MAHSA University and Superior University. 🏅 Dr. Attiq is the recipient of prestigious awards including the APEX Young Scholar 2025 and has published extensively in Q1 journals. He also supervises multiple postgraduate research projects focused on cancer immunotherapy and inflammatory diseases.
Publication Profile
Scopus
💼 Professional Experience
Dr. Ali Attiq brings extensive academic and leadership experience in pharmacology and toxicology. 🧬 Currently serving as a Senior Lecturer at Universiti Sains Malaysia (Nov 2022–Present), he teaches immunopharmacology and conducts pioneering research on epigenetic reprogramming of immune cells in the tumor microenvironment. 🧑🏫 Previously, he was Head of Department and PhD Program Coordinator at MAHSA University (2019–2022), where he led a skilled team, mentored faculty, and explored inflammation-related molecular pathways. 🔬 Earlier, at Superior University (2014–2015), he taught clinical and applied pharmacology, guided research projects, and championed patient-centered care among pharmacy students.
🎓 Educational Background
Dr. Ali Attiq holds a PhD in Pharmacy with a focus on Immunopharmacology and Drug Discovery from Universiti Kebangsaan Malaysia (2019), where he discovered novel anti-inflammatory compounds and developed in-vitro models for preclinical disease analysis. 🔬 He earned his M.Phil in Pharmacology and Toxicology from the University of Veterinary & Animal Sciences (2014), gaining expertise in FDA-approved assays such as the Ames test, gel electrophoresis, comet assay, and cytotoxicity testing. 🧪 His academic journey began with a PharmD from Hamdard University (2012), where he developed a strong foundation in patient-centered care and clinical pharmacology
🏆 Awards and Achievements
Dr. Ali Attiq has earned several prestigious accolades throughout his academic journey. 🌟 He was named an APEX Young Scholar (AYS) in 2025 by the Research Creativity and Management Office (RCMO), recognizing his excellence in research and innovation and commitment to future academic leadership. 🎓 In 2015, he secured 1st position as Best Oral Presenter at the 3rd International Conference on Enduring Health Sciences Research (ICEHSR) for his impactful master’s research. 🗣️ Earlier, in 2013, he received the esteemed Youth Initiative Award from the Government of Pakistan, becoming the youngest recipient of the Chief Minister Punjab’s honor.
🧪 Research Focus
Dr. Ali Attiq’s research is primarily rooted in immunopharmacology, with a special focus on inflammation, dysbiosis-induced disorders, and drug discovery. 🔬 He explores the molecular mechanisms of immune responses, particularly the epigenetic reprogramming of immune cells in the tumour microenvironment. 🧬 His work also delves into NF-κB signaling, cytokine storms, and cardiovascular inflammation, such as in atherosclerosis and coronary artery disease. ❤️🔥 His publications reveal a deep interest in how early-life antibiotic exposures contribute to microbiome dysregulation and chronic diseases. 💊 Through cutting-edge research, Dr. Attiq aims to design innovative therapies targeting inflammation at its molecular root.
Publication Top Notes
📄 Neuroinflammation to neurodegeneration: Boulevard of broken nerves (2025)
📄 Early-Life Antibiotic Exposures: Paving the Pathway for Dysbiosis-Induced Disorders (2025)
📄 Sansevieria trifasciata extract: Antimicrobial & cytotoxic potential (2024)
📄 Cytokine Storm-Induced Thyroid Dysfunction in COVID-19 (2024)
📄 Interaction between Nuclear Receptor and Adrenergic Agonists in Hypertensive Rats (2024)
📄 Platinum-based chemotherapies & cisplatin resistance in NSCLC (2024)
📄 Hegemony of inflammation in atherosclerosis and coronary artery disease (2024) – 58 citations
📄 Oxidative stress & reactive oxygen species in disorders (2023)
📄 Trinity of inflammation & immune signaling in tumor microenvironment (2023)
📄 Adiponectin receptor and renal vasculature in diabetes (2022)
📄 NF-κB, inflammation & cytokine storm in COVID-19 (2021) – ~200+ citations
📄 Anti-cancer activities of lycopene (2021)